Related Experiment Video

Updated: May 25, 2026

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

New biologic agents for the treatment of gynecologic cancers

Neil Horowitz1, Ursula A Matulonis

  • 1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA 02115, USA.

Hematology/Oncology Clinics of North America
|January 17, 2012
PubMed

Insights

New targeted biologic agents offer a promising approach for gynecologic cancers, matching treatments to tumor histology or genetics. Combinations with chemotherapy and other pathway inhibitors are under active investigation.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Gynecologic malignancies present a significant challenge in cancer treatment.
  • The development of targeted therapies has revolutionized cancer care.
  • Personalized medicine approaches are increasingly important in oncology.

Purpose of the Study:

  • To explore the potential of new biologic targeted agents in gynecologic cancer treatment.
  • To investigate the matching of these agents based on tumor histology and genetic profiles.
  • To review current research on therapeutic targets and combination strategies.

Main Methods:

  • Review of current scientific literature on targeted biologic agents for gynecologic cancers.
  • Analysis of studies investigating treatment matching based on cancer histology and genetics.
  • Examination of ongoing clinical trials for combination therapies.

Main Results:

  • New biologic targeted agents represent a significant advancement in gynecologic oncology.
  • Matching treatments to specific tumor characteristics (histology, genetics) is crucial for efficacy.
  • Multiple therapeutic pathways are being explored for targeted treatment.
  • Combination therapies, including with chemotherapy and other pathway inhibitors, are in development.

Conclusions:

  • The precise matching of targeted agents to gynecologic tumor types is a key development.
  • Ongoing research into novel therapeutic targets and combination strategies holds significant promise.
  • This evolving landscape offers new hope for improved patient outcomes in gynecologic malignancies.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...